Amgen Inc (AMGN) stock
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3022% above fair value
$465.67−1.39 (-0.30%)
Close on Nov 13, 2026Market cap $251.76BP/E 27.0Yield 2.07%
Amgen operating margin
Operating margin is operating income as a percentage of revenue.
Amgen's operating margin for the twelve months ending Sep 30, 2026 was 32.4%. For fiscal 2025 it was 24.7%, against 21.7% the year before. The highest annual figure on record is 43.6% in fiscal 2017.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 24.7% | +3.0 |
| FY2024 | Dec 31, 2024 | 21.7% | −6.3 |
| FY2023 | Dec 31, 2023 | 28.0% | −8.3 |
| FY2022 | Dec 31, 2022 | 36.3% | +6.9 |
| FY2021 | Dec 31, 2021 | 29.4% | −6.5 |
| FY2020 | Dec 31, 2020 | 35.9% | −5.5 |
| FY2019 | Dec 31, 2019 | 41.4% | −1.8 |
| FY2018 | Dec 31, 2018 | 43.2% | −0.4 |
| FY2017 | Dec 31, 2017 | 43.6% | +1.0 |
| FY2016 | Dec 31, 2016 | 42.6% | +3.5 |
| FY2015 | Dec 31, 2015 | 39.1% | +8.2 |
| FY2014 | Dec 31, 2014 | 30.9% | −0.6 |
| FY2013 | Dec 31, 2013 | 31.4% | −0.9 |
| FY2012 | Dec 31, 2012 | 32.3% | +4.6 |
| FY2011 | Dec 31, 2011 | 27.7% | −9.2 |
| FY2010 | Dec 31, 2010 | 36.8% | −0.8 |
| FY2009 | Dec 31, 2009 | 37.6% | +2.9 |
| FY2008 | Dec 31, 2008 | 34.8% | +7.8 |
| FY2007 | Dec 31, 2007 | 26.9% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 35.8% | +9.4 |
| Q2 FY2026 | Jun 30, 2026 | 35.0% | +6.0 |
| Q1 FY2026 | Mar 31, 2026 | 30.9% | +16.5 |
| Q4 FY2025 | Dec 31, 2025 | 27.6% | +2.1 |
| Q3 FY2025 | Sep 30, 2025 | 26.4% | +2.4 |
| Q2 FY2025 | Jun 30, 2025 | 28.9% | +6.2 |
| Q1 FY2025 | Mar 31, 2025 | 14.5% | +1.1 |
| Q4 FY2024 | Dec 31, 2024 | 25.4% | +9.9 |
| Q3 FY2024 | Sep 30, 2024 | 24.1% | −5.2 |
| Q2 FY2024 | Jun 30, 2024 | 22.8% | −15.7 |
| Q1 FY2024 | Mar 31, 2024 | 13.3% | −18.2 |
| Q4 FY2023 | Dec 31, 2023 | 15.5% | −17.1 |
| Q3 FY2023 | Sep 30, 2023 | 29.3% | −10.7 |
| Q2 FY2023 | Jun 30, 2023 | 38.4% | +5.4 |
| Q1 FY2023 | Mar 31, 2023 | 31.5% | −8.6 |
| Q4 FY2022 | Dec 31, 2022 | 32.6% | −1.0 |
| Q3 FY2022 | Sep 30, 2022 | 40.0% | +3.9 |
| Q2 FY2022 | Jun 30, 2022 | 33.0% | +2.7 |
| Q1 FY2022 | Mar 31, 2022 | 40.1% | +1.9 |
| Q4 FY2021 | Dec 31, 2021 | 33.7% | −3.8 |
| Q1 FY2021 | Mar 31, 2021 | 36.1% | −2.1 |
| Q4 FY2020 | Dec 31, 2020 | 30.3% | −15.3 |
| Q3 FY2020 | Sep 30, 2020 | 38.2% | −6.3 |
| Q2 FY2020 | Jun 30, 2020 | 37.4% | −0.8 |
| Q1 FY2020 | Mar 31, 2020 | 38.2% | −1.1 |
| Q2 FY2019 | Jun 30, 2019 | 45.6% | −1.1 |
| Q1 FY2019 | Mar 31, 2019 | 44.5% | −4.6 |
| Q4 FY2018 | Dec 31, 2018 | 38.2% | −2.1 |
| Q3 FY2018 | Sep 30, 2018 | 39.3% | −2.9 |
| Q2 FY2018 | Jun 30, 2018 | 46.7% | +0.3 |
| Q1 FY2018 | Mar 31, 2018 | 49.1% | +1.7 |
| Q4 FY2017 | Dec 31, 2017 | 40.3% | −3.6 |
| Q3 FY2017 | Sep 30, 2017 | 42.2% | −3.6 |
| Q2 FY2017 | Jun 30, 2017 | 46.4% | +3.0 |
| Q1 FY2017 | Mar 31, 2017 | 47.4% | – |
| Q4 FY2016 | Dec 31, 2016 | 43.9% | – |
| Q3 FY2016 | Sep 30, 2016 | 45.8% | – |
| Q2 FY2016 | Jun 30, 2016 | 43.5% | – |
See a number that looks wrong?